Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RELA vs BACLOFEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
RELA (Carisoprodol) is a centrally acting muscle relaxant that modulates GABA-A receptor activity and blocks interneuronal activity in the descending reticular formation and spinal cord, resulting in muscle relaxation without directly affecting the neuromuscular junction. Its metabolite, meprobamate, contributes to anxiolytic and sedative effects.
GABA-B receptor agonist; inhibits monosynaptic and polysynaptic spinal reflexes by hyperpolarizing afferent terminals.
Adjunctive treatment for acute musculoskeletal pain due to muscle spasm (FDA approved),Off-label: Tension headaches, fibromyalgia, myofascial pain syndrome
Spasticity due to multiple sclerosis (FDA approved),Spinal cord injury (FDA approved),Intrathecal use for severe spasticity of cerebral origin (off-label),Hiccups (off-label),Alcohol withdrawal syndrome (off-label),Trigeminal neuralgia (off-label)
Adults: 250-350 mg orally 3-4 times daily.
Initial: 5 mg orally 3 times daily; increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg 4 times daily). Intrathecal: initial test dose 50-100 mcg; for continuous infusion, daily dose typically 300-800 mcg.
Terminal elimination half-life approximately 20–30 hours; prolonged in elderly and renal impairment
Terminal half-life: 2.5-4 hours (young adults), 4-8 hours (elderly); clinical context: requires frequent dosing for spasticity.
Hepatic metabolism via CYP2C19 to meprobamate (active); also minor pathways via CYP3A4 and CYP1A2. Meprobamate is further hydroxylated and glucuronidated.
Metabolized via hepatic deamination by transaminase; primarily excreted unchanged in urine (approximately 70-80%), with minor hepatic metabolism.
Primarily renal excretion of unchanged drug and metabolites; 70% to 80% eliminated via urine, remainder biliary/fecal
Renal: 70-80% unchanged; fecal: <5%; biliary: minimal.
99% bound to albumin and alpha-1-acid glycoprotein
30-35% bound to albumin.
0.1–0.2 L/kg; indicates limited distribution in total body water
Vd: 0.5-0.7 L/kg; indicates distribution into total body water.
Oral: 80–90%; Intramuscular: 100%
Oral: 70-85% with high variability; intrathecal: 100%.
GFR 10-50 m L/min: administer 250 mg every 6-8 hours; GFR <10 m L/min: administer 250 mg every 12-24 hours.
Cr Cl 30-50 m L/min: reduce dose by 50%; Cr Cl <30 m L/min: avoid use or use with extreme caution, reduce dose by 75%.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% and monitor; Class C: avoid use.
No specific guidelines; use with caution due to potential for increased sedation/neurotoxicity.
Children 2-12 years: 10-20 mg/kg/day divided every 6-8 hours; maximum 1.5 g/day.
Children 2-7 years: initial 2.5 mg orally 4 times daily, increase by 2.5 mg/dose every 3 days to max 40 mg/day; children ≥8 years: initial 5 mg orally 3 times daily, increase as in adults to max 60 mg/day.
Start at lower end of adult dosing (250 mg 3 times daily); monitor for CNS effects and adjust based on renal function.
Start at low end of dosing range (5 mg twice daily), titrate slowly due to increased risk of sedation, weakness, and cognitive impairment.
None explicitly required by FDA; however, dependence, withdrawal, and abuse potential are significant due to meprobamate metabolite, leading to controlled substance scheduling (Schedule IV).
Abrupt discontinuation may cause withdrawal symptoms including hallucinations, seizures, and life-threatening hyperpyrexia; taper dose gradually.
Risk of dependence, withdrawal (including seizures, anxiety, insomnia) after prolonged use; CNS depression (additive with alcohol and other depressants); impaired motor skills; caution in hepatic or renal impairment; elderly patients more sensitive; avoid abrupt discontinuation.
May cause CNS depression (drowsiness, sedation) and impair ability to drive or operate machinery.,Risk of withdrawal syndrome including fever, altered mental status, and autonomic instability upon abrupt cessation.,Use with caution in patients with renal impairment; dose adjustment required.,May exacerbate psychiatric disorders; monitor for hallucinations, confusion.,Risk of respiratory depression when combined with other CNS depressants.
Hypersensitivity to carisoprodol or meprobamate; acute intermittent porphyria; concurrent use with MAO inhibitors (theoretical interaction). Relative: history of substance abuse, severe hepatic or renal disease, poor CYP2C19 metabolizers.
Hypersensitivity to baclofen.,Intrathecal formulation is contraindicated in patients with active infection or bleeding disorders at lumbar puncture site.,Women who are breastfeeding (relative contraindication).
No specific food interactions. However, avoid alcohol as it increases sedation and respiratory depression risk.
No specific food interactions. Avoid alcohol due to additive CNS depression.
Carisoprodol, the active ingredient in RELA, is classified as FDA Pregnancy Category C. Animal studies have shown an increased incidence of fetal resorptions and skeletal variants at doses 4-5 times the human dose. There are no adequate and well-controlled studies in pregnant women. First trimester: Risk cannot be ruled out; use only if clearly needed. Second and third trimesters: May cause neonatal withdrawal syndrome or respiratory depression if used near term. Discontinue use if pregnancy occurs.
First trimester: Limited human data; animal studies show increased fetal malformations (omphalocele, exencephaly) at doses equivalent to human therapeutic range. Second and third trimesters: Risk of neonatal withdrawal (hypertonia, seizures) with chronic maternal use. Avoid unless benefit outweighs risk.
Carisoprodol and its active metabolite meprobamate are excreted in human breast milk. The milk-to-plasma ratio for meprobamate is approximately 2-4. Based on limited data, a nursing infant would receive about 1-3% of the maternal weight-adjusted dose. Consider the potential for infant sedation or feeding difficulties. Use caution in breastfeeding women, especially with high doses or prolonged use.
Baclofen excreted into breast milk in low concentrations (M/P ratio approximately 0.43). Relative infant dose estimated 0.9% of maternal weight-adjusted dose. Considered compatible with breastfeeding, but monitor infant for sedation and hypotonia.
Pharmacokinetic changes in pregnancy (increased volume of distribution, increased renal clearance, altered hepatic metabolism) may increase carisoprodol clearance. Reduce steady-state concentrations; however, no specific dosing adjustments are recommended due to lack of data. Use the lowest effective dose for the shortest duration. Avoid during labor and delivery due to risk of neonatal respiratory depression.
No specific dose adjustments recommended. Increased renal blood flow and GFR in pregnancy may reduce baclofen levels; monitor clinical effect and adjust dose as needed. Avoid abrupt discontinuation due to risk of maternal withdrawal and rebound spasticity.
RELA (carisoprodol) is a centrally acting muscle relaxant metabolized to meprobamate, a controlled substance. Monitor for sedation and abuse potential. Avoid concurrent use with CNS depressants including alcohol. Sudden discontinuation after prolonged use may precipitate withdrawal symptoms.
Abrupt withdrawal can cause severe rebound spasticity, fever, and rhabdomyolysis; taper by 5-10 mg/week. Intrathecal baclofen pumps require careful monitoring for overdose (respiratory depression) or withdrawal. Use with caution in renal impairment (dose adjust for Cr Cl <30 m L/min).
This medication may cause drowsiness or dizziness. Do not drive or operate heavy machinery until you know how it affects you.,Avoid alcohol and other CNS depressants while taking this drug.,Take only as prescribed; do not increase dose or duration due to risk of dependence.,Do not stop abruptly after long-term use; consult your doctor for a taper schedule.
Do not stop taking baclofen suddenly; sudden discontinuation can cause serious withdrawal symptoms including hallucinations, seizures, and high fever.,Avoid alcohol and CNS depressants as they increase sedation and risk of falls.,May cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.,Take exactly as prescribed; missed doses can lead to muscle spasms or withdrawal.,Report any unusual muscle stiffness, rapid heart rate, or dark urine immediately.
No interactions on record
"Sevoflurane enhances the inhibitory effects of baclofen on the central nervous system by potentiating GABA-B receptor activity, leading to an increased risk of profound sedation, respiratory depression, and hypotension. This synergistic interaction can result in prolonged recovery from anesthesia and the need for ventilatory support. Clinically, patients may exhibit exaggerated muscle relaxation and a delayed emergence from anesthesia, particularly at higher doses of either agent."
"Concomitant use of etidocaine, an amide-type local anesthetic that blocks voltage-gated sodium channels, and baclofen, a GABAB receptor agonist used for muscle spasticity, may lead to additive central nervous system (CNS) depression and respiratory depression. This interaction results from synergistic depressant effects on the brainstem and spinal cord, increasing the risk of sedation, dizziness, ataxia, and impaired consciousness. Clinically, patients may experience excessive drowsiness, respiratory compromise, and impaired motor coordination, particularly in the elderly or those with pre-existing renal impairment where baclofen accumulation is more likely."
"The coadministration of Baclofen and Metaxalone results in additive central nervous system (CNS) depression due to their shared pharmacodynamic effects on GABAergic and sedative pathways. This combination can potentiate sedation, dizziness, ataxia, and respiratory depression, particularly in elderly patients or those with renal impairment. Clinical outcomes may include increased risk of falls, cognitive impairment, and impaired motor coordination, necessitating cautious dose titration."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RELA vs BACLOFEN, answered by our medical review team.
RELA is a Skeletal Muscle Relaxant that works by RELA (Carisoprodol) is a centrally acting muscle relaxant that modulates GABA-A receptor activity and blocks interneuronal activity in the descending reticular formation and spinal cord, resulting in muscle relaxation without directly affecting the neuromuscular junction. Its metabolite, meprobamate, contributes to anxiolytic and sedative effects.. BACLOFEN is a Skeletal Muscle Relaxant that works by GABA-B receptor agonist; inhibits monosynaptic and polysynaptic spinal reflexes by hyperpolarizing afferent terminals.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RELA and BACLOFEN depend on the specific clinical indication. These are both Skeletal Muscle Relaxant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RELA is: Adults: 250-350 mg orally 3-4 times daily.. The standard adult dose of BACLOFEN is: Initial: 5 mg orally 3 times daily; increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg 4 times daily). Intrathecal: initial test dose 50-100 mcg; for continuous infusion, daily dose typically 300-800 mcg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RELA and BACLOFEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RELA is classified as Category C. Carisoprodol, the active ingredient in RELA, is classified as FDA Pregnancy Category C. Animal studies have shown an increased incidence of fetal resorptions and skeletal variants . BACLOFEN is classified as Category C. First trimester: Limited human data; animal studies show increased fetal malformations (omphalocele, exencephaly) at doses equivalent to human therapeutic range. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.